Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
ClinicalTrials.gov · NCT05220917 · Registry updated: 2026-08-13
- Condition / research focus
- Cardiovascular Events; Type2 Diabetes; Renal Disease
- Sponsor
- Brigham and Women's Hospital
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2021-08-01. Completion: 2027-09-30 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- SGLT2 inhibitor (drug) — also listed as: CANAGLIFLOZIN, CANAGLIFLOZIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL, EMPAGLIFLOZIN, EMPAGLIFLOZIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE
- DPP-4 inhibitor (drug) — also listed as: ALOGLIPTIN BENZOATE/METFORMIN HCL, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE/PIOGLITAZONE HCL, SAXAGLIPTIN HCL, SAXAGLIPTIN HCL/METFORMIN HCL, LINAGLIPTIN, LINAGLIPTIN/METFORMIN HCL, SITAGLIPTIN PHOSPHATE/METFORMIN HCL, SITAGLIPTIN PHOSPHATE, SITAGLIPTIN PHOSPHATE/SIMVASTATIN, DAPAGLIFLOZIN PROPANEDIOL/SAXAGLIPTIN HCL, EMPAGLIFLOZIN/LINAGLIPTIN, EMPAGLIFLOZIN/LINAGLIPTIN/METFORMIN HCL, ERTUGLIFLOZIN PIDOLATE/SITAGLIPTIN PHOSPHATE